TNG Transgene SA

Transgene Announces Upcoming Investor Meetings

STRASBOURG, France--(BUSINESS WIRE)--

Regulatory News:

TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.

Transgene will meet institutional investors at the 12th Annual LifeSci Advisors Corporate Access Event and at BIO Partnering at JPM in San Francisco from January 9 to 12, 2023, in conjunction with the J.P. Morgan Healthcare conference.

The Company will also attend:

  • 26th ODDO BHF Forum (virtual): January 9-10, 2023;
  • Invest Securities Biomed Forum: January 24, 2023;
  • Degroof Petercam’s Virtual Healthcare Conference: January 27, 2023;
  • BIO CEO & Investor Forum (New York): February 6-9, 2023.

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).

With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.

Additional information about Transgene is available at:

Follow us on Twitter:

EN
15/12/2022

Underlying

TNGTransgene SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene to Present New Immunological Data from Phase I Trial of Indi...

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025 Strasbourg, France, October 3, 2025, 5:45 p.m.  CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will tak...

October 3, 2025 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene présente de nouvelles données d’immunologie de la Phase I de...

Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, son vaccin thérapeutique individualisé, au SITC 2025 Strasbourg, France, le 3 octobre 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, présente un poster, à la 40e conférence annuelle de la Société pour l’immunothérapie du cancer (SITC) mettant en avant l’analyse approfondie de la réponse cellulaire T spécifique des néoantigènes issue de l’essai randomisé de Phase I de son vaccin thérapeutiqu...

October 3, 2025 1 EN
Jerôme Bodin ... (+2)
  • Jerôme Bodin
  • Thomas Zlowodzki
TKA THYSSENKRUPP AG
GTT GAZTRANSPORT & TECHNIGAZ SA
TNG TRANSGENE SA
ASY ASSYSTEM SA
PSM PROSIEBENSAT.1 MEDIA SE
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SHA SCHAEFFLER AG
09/17/25 September 17, 2025 1 EN
Jerôme Bodin ... (+2)
  • Jerôme Bodin
  • Thomas Zlowodzki
GTT GAZTRANSPORT & TECHNIGAZ SA
TNG TRANSGENE SA
ASY ASSYSTEM SA
PSM PROSIEBENSAT.1 MEDIA SE
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SHA SCHAEFFLER AG
09/17/25 September 17, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
09/17/25 September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch